Biohaven
BHVN

Biohaven (BHVN) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Morgan StanleyMaintainedOverweight$19.00 from $18.00Aug 12, 2026
RBC CapitalMaintainedOutperform$23.00 from $22.00Aug 11, 2026
B of A SecuritiesDowngradedNeutral → Underperform$11.00 from $12.00Jun 29, 2026
HC Wainwright & Co.MaintainedNeutral$10.00May 26, 2026
Morgan StanleyMaintainedOverweight$18.00 from $21.00May 13, 2026
RBC CapitalMaintainedOutperform$22.00 from $23.00May 5, 2026
CitigroupMaintainedBuy$17.00 from $14.00Apr 2, 2026
TD CowenMaintainedBuy$30.00 from $15.00Mar 11, 2026
HC Wainwright & Co.MaintainedNeutral$10.00 from $11.00Mar 4, 2026
RBC CapitalMaintainedOutperform$23.00 from $22.00Mar 3, 2026
RBC CapitalUpgradedSector Perform → Outperform$22.00 from $9.00Jan 21, 2026
Morgan StanleyMaintainedOverweight$21.00 from $26.00Jan 6, 2026
HC Wainwright & Co.MaintainedNeutral$11.00Dec 26, 2025
HC Wainwright & Co.DowngradedBuy → Neutral$11.00 from $30.00Dec 3, 2025
UBSDowngradedBuy → Neutral$11.00 from $26.00Nov 26, 2025
JP MorganMaintainedOverweight$15.00 from $47.00Nov 20, 2025
BTIGMaintainedBuy$16.00Nov 18, 2025
Morgan StanleyMaintainedOverweight$26.00 from $54.00Nov 18, 2025
CitigroupMaintainedBuy$14.00 from $28.00Nov 13, 2025
BTIGMaintainedBuy$16.00 from $33.00Nov 6, 2025

Frequently asked questions

  • What is the latest analyst rating on BHVN?

    On Aug 12, 2026, Morgan Stanley maintained Biohaven at Overweight with a price target of $19.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.